Abstract
India, popularly described as ‘the pharmacy of the developing world’ both because of it huge market in generic medicines and its developing research-based pharmaceutical industry, has since 2007 been in negotiations to agree on the provisions of a bilateral Free Trade Agreement (FTA) with the European Union (EU). David Martin, with fellow MEPs and a network of public health groups, is calling on the EU Commission to ensure that demands on India to take on higher intellectual property (IP) standards within the terms of the FTA should not undermine the supply of low-cost generic medicines to the poor and suffering of the developing world or set a precedent for the future of IP protection globally.
Keywords
Get full access to this article
View all access options for this article.